Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.55 USD | -1.93% | -0.84% | -18.95% |
May. 09 | Transcript : Eton Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
May. 09 | Eton Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Financials (USD)
Sales 2024 * | 36.1M | Sales 2025 * | 47.4M | Capitalization | 91.2M |
---|---|---|---|---|---|
Net income 2024 * | -1M | Net income 2025 * | 7M | EV / Sales 2024 * | 2.53 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.92 x |
P/E ratio 2024 * |
-59.2
x | P/E ratio 2025 * |
13.1
x | Employees | 30 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.58% |
Latest transcript on Eton Pharmaceuticals, Inc.
1 day | -1.93% | ||
1 week | -0.84% | ||
1 month | +1.43% | ||
3 months | -20.22% | ||
6 months | +0.28% | ||
Current year | -18.95% |
Managers | Title | Age | Since |
---|---|---|---|
Sean Brynjelsen
CEO | Chief Executive Officer | 52 | 17-05-31 |
James Gruber
DFI | Director of Finance/CFO | 52 | 22-04-10 |
Lisa M. Wilson
IRC | Investor Relations Contact | 59 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 78 | 17-05-31 | |
Paul Maier
BRD | Director/Board Member | 76 | 17-09-13 |
Norbert Riedel
CHM | Chairman | 66 | 17-09-06 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 3.55 | -1.93% | 21,338 |
24-05-30 | 3.62 | -2.16% | 51,664 |
24-05-29 | 3.7 | +2.78% | 24,808 |
24-05-28 | 3.6 | +0.56% | 38,877 |
24-05-24 | 3.58 | -0.56% | 224,449 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.95% | 91.2M | |
+15.54% | 78.51B | |
+12.05% | 9B | |
+58.17% | 4.96B | |
-14.94% | 4.84B | |
-.--% | 3.72B | |
+21.94% | 2.48B | |
-26.63% | 2.19B | |
+16.75% | 2.12B | |
-37.97% | 1.94B |
- Stock Market
- Equities
- ETON Stock